Langham Max Raymond, Kays David William, Beierle Elizabeth Ann, Chen Mike K, Stringfellow Karla, Talbert James Lewis
Division of Pediatric Surgery, Department of Surgery, University of Florida College of Medicine, J-100286, Gainesville, FL 32610-0286, USA.
Ann Surg. 2003 Jun;237(6):766-72; discussion 772-4. doi: 10.1097/01.SLA.0000067740.05989.45.
To examine the breadth of application and resulting outcomes in a university-based extracorporeal membrane oxygenation (ECMO) program directed by pediatric surgeons.
Several randomized control trials have supported the use of ECMO in neonates with respiratory failure. No comparable data exist for older children and young adults who may be afflicted with a variety of uncommon conditions. The indications for ECMO in these patients remain controversial.
Patient data were recorded prospectively and reported to the Extracorporeal Life Support Organization. These data were analyzed by indications and outcomes on all patients treated since the inception of the program.
Two hundred sixteen patients were treated with 225 courses of ECMO. Neonates (188 [87%]) outnumbered 28 older patients (aged 6 weeks to 22 years). Overall, 174 patients survived (81%). Sixty-four of 65 (98.5%) neonates with meconium aspiration syndrome survived. ECMO support after heart (3), lung (2), heart-lung (1), and liver (1) transplant yielded a 57% survival to discharge. ECMO also resulted in survival of patients with uncommon conditions, including severe asthma (1), hydrocarbon aspiration (1/2), congestive heart failure due to a cerebral arteriovenous malformation (1), tracheal occlusion incurred during endoscopic stent manipulation (2), meningitis (1), and viral pneumonia (3/5).
ECMO can potentially eliminate mortality for meconium aspiration syndrome. Survival for other causes of respiratory failure in neonates and older children, while not as dramatic, still surpasses that anticipated with conventional therapy. Moreover, survival of transplant patients has been comparable to that achieved in other children.
探讨在小儿外科医生主导的大学体外膜肺氧合(ECMO)项目中的应用范围及最终结果。
多项随机对照试验支持在呼吸衰竭新生儿中使用ECMO。对于可能患有各种罕见疾病的大龄儿童和青年,尚无类似数据。这些患者使用ECMO的指征仍存在争议。
前瞻性记录患者数据并报告给体外生命支持组织。对该项目启动以来所有接受治疗患者的指征和结果进行分析。
216例患者接受了225个疗程的ECMO治疗。新生儿(188例[87%])数量超过28例大龄患者(6周龄至22岁)。总体而言,174例患者存活(81%)。65例胎粪吸入综合征新生儿中有64例(98.5%)存活。心脏(3例)、肺(2例)、心肺联合(1例)和肝脏(1例)移植术后接受ECMO支持的患者出院生存率为57%。ECMO还使患有罕见疾病的患者存活,包括重症哮喘(1例)、碳氢化合物吸入(2例中的1例)、脑动静脉畸形导致的充血性心力衰竭(1例)、内镜支架操作时发生的气管阻塞(2例)、脑膜炎(1例)和病毒性肺炎(5例中的3例)。
ECMO有可能消除胎粪吸入综合征的死亡率。新生儿和大龄儿童因其他原因导致的呼吸衰竭患者的生存率虽不那么显著,但仍超过传统治疗预期。此外,移植患者的生存率与其他儿童相当。